Nav: Home

Clinical efficacy & future development of continuous glucose monitoring highlighted in DTT

June 07, 2017

New Rochelle, NY, June 7, 2017--A growing body of data from clinical studies of continuous glucose monitoring (CGM) in type 1 diabetes supports the value of CGM for reducing variability in blood glucose levels and the risks of both hypo- and hyperglycemia, and for improving patient quality of life compared to self-monitoring of blood glucose (SMBG). A review of recent CGM trials and the impact of CGM accuracy on the future of automated insulin delivery systems are the focus of two in a series of articles published as a special supplement to Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The supplement is available open access on the DTT website.

In the article entitled "Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes," David Rodbard, MD, Biomedical Informatics Consultants, Potomac, MD, concluded that CGM, as well as flash glucose monitoring, has been shown to be safe and effective, with the recent regulatory approval of certain CGM devices for nonadjunctive use to guide insulin dose adjustment representing a major advance.

In the "Future of Automated Insulin Delivery Systems," Jessica Castle, MD, Oregon Health & Science University, Portland, J. Hans DeVries, MD, University of Amsterdam, The Netherlands, and Boris Kovatchev, PhD, University of Virginia, Charlottesville, discuss how CGM has enabled the automation of insulin delivery. The authors describe the rapid progress in the development of automated insulin delivery systems, the novel features and advantages they may offer for improving glycemic control, and the critical role that highly accurate CGM will play in the safe and effective use of these systems.

In the Editorial entitled "The Future of Continuous Glucose," DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora) states: "Continuous glucose monitors have come a long way with significant improvement in accuracy and MARD of <10%." Just like all patients with new-onset T1D [type 1 diabetes] get an SMBG meter today, we hope in the very near future, all patients with new-onset T1D will receive CGM."

Research reported in this publication was supported by the National Institutes of Health under Award Number 1DP3DK101044-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
This supplement was supported by an educational grant from Dexcom. Dexcom G5 is the first and currently only CGM approved for nonadjunctive use in the US.

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT)website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Blood Glucose Articles:

Research elucidates hormone ghrelin's role in blood glucose regulation
UT Southwestern research investigating the blood glucose-regulatory actions of the hormone ghrelin may have implications for development of new treatments for diabetes.
Bio-sensing contact lens could someday measure blood glucose, other bodily functions
Transparent biosensors embedded into contact lenses could soon allow doctors and patients to monitor blood glucose levels and a host of other telltale signs of disease without invasive tests.
Convenient and easy to use glucose monitoring and maintenance
A research group from the Center for Nanoparticle Research within the Institute for Basic Science has developed a convenient and accurate sweat-based glucose monitoring and maintenance device.
How rare sugars might help control blood glucose
In an era when the label 'natural' hits a sweet spot with consumers, some uncommon sugars emerging on the market could live up to the connotation.
Continuous glucose monitoring lowers blood sugar in the long term for type 1 diabetes
Significantly decreased blood sugar levels over time -- and increased well-being.
Low blood glucose levels in hospitalized patients linked to increased mortality risk
In hospitalized patients, low blood sugar -- also known as hypoglycemia -- is associated with increased short- and long-term mortality risk, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Noninvasive blood glucose monitoring device for people with diabetes in development
People with diabetes are one step closer to more easily checking their blood glucose levels with a non-invasive device for detecting and monitoring blood glucose levels, which is currently in development.
Bioengineers' sweat sensor monitors glucose
Researchers at the University of Texas at Dallas are sweating the small stuff in their efforts to develop a wearable device that can monitor an individual's glucose level via perspiration on the skin.
Combination therapy for type 1 diabetes improves blood glucose control
A combination of three medications -- dapagliflozin, liraglutide and insulin -- helped people with Type 1 diabetes improve blood sugar control and lose weight, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Glucose transporters blocked in bacterial meningitis
CHLA researchers report that glucose transporters, which transfer glucose from the blood to the brain, are inhibited by E. coli K1 during bacterial meningitis, leaving insufficient fuel for immune cells to fight off infection.

Related Blood Glucose Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.